Iron status and the risk of sepsis and severe COVID-19: a two-sample Mendelian randomization study.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
28 09 2022
28 09 2022
Historique:
received:
04
07
2022
accepted:
16
09
2022
entrez:
28
9
2022
pubmed:
29
9
2022
medline:
1
10
2022
Statut:
epublish
Résumé
Observational studies have indicated an association between iron status and risk of sepsis and COVID-19. We estimated the effect of genetically-predicted iron biomarkers on risk of sepsis and risk of being hospitalized with COVID-19, performing a two-sample Mendelian randomization study. For risk of sepsis, one standard deviation increase in genetically-predicted serum iron was associated with odds ratio (OR) of 1.14 (95% confidence interval [CI] 1.01-1.29, P = 0.031). The findings were supported in the analyses for transferrin saturation and total iron binding capacity, while the estimate for ferritin was inconclusive. We found a tendency of higher risk of hospitalization with COVID-19 for serum iron; OR 1.29 (CI 0.97-1.72, P = 0.08), whereas sex-stratified analyses showed OR 1.63 (CI 0.94-2.86, P = 0.09) for women and OR 1.21 (CI 0.92-1.62, P = 0.17) for men. Sensitivity analyses supported the main findings and did not suggest bias due to pleiotropy. Our findings suggest a causal effect of genetically-predicted higher iron status and risk of hospitalization due to sepsis and indications of an increased risk of being hospitalized with COVID-19. These findings warrant further studies to assess iron status in relation to severe infections, including the potential of improved management.
Identifiants
pubmed: 36171422
doi: 10.1038/s41598-022-20679-6
pii: 10.1038/s41598-022-20679-6
pmc: PMC9516524
doi:
Substances chimiques
Biomarkers
0
Transferrin
0
Ferritins
9007-73-2
Iron
E1UOL152H7
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
16157Informations de copyright
© 2022. The Author(s).
Références
Beard, J. L. Iron biology in immune function, muscle metabolism and neuronal functioning. J. Nutr. 131, 568S-579S (2001).
Ganz, T. & Nemeth, E. Iron homeostasis in host defence and inflammation. Nat. Rev. Immunol. 15, 500–510 (2015).
WHO. WHO Guideline on Use of Ferritin Concentrations to Assess Iron Status in Individuals and Populations (World Health Organization, 2020).
WHO. Assessing the Iron Status of Populations: Including Literature Reviews (World Health Organization, 2007).
Tansarli, G. S., Karageorgopoulos, D. E., Kapaskelis, A., Gkegkes, I. & Falagas, M. E. Iron deficiency and susceptibility to infections: Evaluation of the clinical evidence. Eur. J. Clin. Microbiol. Infect. Dis. 32, 1253–1258 (2013).
Mohus, R. M. et al. Association of iron status with the risk of bloodstream infections: Results from the prospective population-based HUNT study in Norway. Intensive Care Med. 44, 1276–1283 (2018).
Brandtner, A. et al. Linkage of alterations in systemic iron homeostasis to patients’ outcome in sepsis: A prospective study. J. Intensive Care 8, 76 (2020).
Akkaş, İ, Ince, N. & Sungur, M. A. Serum trace element and heavy metal levels in patients with sepsis. Aging Male 23, 222–226 (2020).
Lan, P. et al. High serum iron level is associated with increased mortality in patients with sepsis. Sci. Rep. 8, 11072 (2018).
Swenson, E. R., Porcher, R. & Piagnerelli, M. Iron deficiency and infection: Another pathway to explore in critically ill patients? Intensive Care Med. 44, 2260–2262 (2018).
Drakesmith, H. & Prentice, A. M. Hepcidin and the iron-infection axis. Science 338, 768–772 (2012).
Singer, M. et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA 315, 801–810 (2016).
da Silva Ramos, F. J., de Freitas, F. G. R. & Machado, F. R. Sepsis in patients hospitalized with coronavirus disease 2019: How often and how severe? Curr. Opin. Crit. Care 27, 474–479 (2021).
Lv, Y. et al. Association between iron status and the risk of adverse outcomes in COVID-19. Clin. Nutr. 40, 3462–3469 (2021).
Hippchen, T., Altamura, S., Muckenthaler, M. U. & Merle, U. Hypoferremia predicts hospitalization and oxygen demand in COVID-19 patients. MedRxiv 8(4), 420 (2020).
Perricone, C. et al. COVID-19 as part of the hyperferritinemic syndromes: The role of iron depletion therapy. Immunol. Res. 68, 213–224 (2020).
Tojo, K. et al. The U-shaped association of serum iron level with disease severity in adult hospitalized patients with COVID-19. Sci. Rep. 11, 13431 (2021).
Galmés, S., Serra, F. & Palou, A. Current state of evidence: Influence of nutritional and nutrigenetic factors on immunity in the COVID-19 pandemic framework. Nutrients 12(9), 2738 (2020).
Mohus, R. M. et al. Explaining sex differences in risk of bloodstream infections using mediation analysis in the population-based HUNT study in Norway. Sci. Rep. 12, 8436 (2022).
Alwani, M. et al. Sex-based differences in severity and mortality in COVID-19. Rev. Med. Virol. 31, e2223 (2021).
Peckham, H. et al. Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. Nat. Commun. 11, 6317 (2020).
Davies, N. M., Holmes, M. V. & Davey Smith, G. Reading Mendelian randomisation studies: A guide, glossary and checklist for clinicians. BMJ 362, k601 (2018).
Hu, Y. et al. Causal effects of genetically predicted iron status on sepsis: A two-sample bidirectional Mendelian randomization study. Front. Nutr. 8, 747547 (2021).
Bell, S. et al. A genome-wide meta-analysis yields 46 new loci associating with biomarkers of iron homeostasis. Commun. Biol. 4, 156 (2021).
Mauvais-Jarvis, F. et al. Sex and gender: Modifiers of health, disease and medicine. Lancet 396, 565–582 (2020).
Burgess, S. & Thompson, S. G. Avoiding bias from weak instruments in Mendelian randomization studies. Int. J. Epidemiol. 40, 755–764 (2011).
Hemani, G. et al. The MR-Base platform supports systematic causal inference across the human phenome. Elife. https://doi.org/10.7554/eLife.34408 (2018).
doi: 10.7554/eLife.34408
Yavorska, O. O. & Burgess, S. MendelianRandomization: An R package for performing Mendelian randomization analyses using summarized data. Int. J. Epidemiol. 46, 1734–1739 (2017).
Rudd, K. E. et al. Global, regional and national sepsis incidence and mortality, 1990–2017: Analysis for the global burden of disease study. Lancet 395, 200–211 (2020).
Elsworth, B. et al. The MRC IEU OpenGWAS data infrastructure. BioRxiv 35, 99 (2020).
Niemi, M. E. K., Karjalainen, J., Neale, B. M., Daly, M. & Andrea, G. Mapping the human genetic architecture of COVID-19. Nature 600, 472–477 (2021).
Machiela, M. J. & Chanock, S. J. LDlink: A web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants. Bioinformatics 31, 3555–3557 (2015).
Hartwig, F. P., Davies, N. M., Hemani, G. & Davey Smith, G. Two-sample Mendelian randomization: Avoiding the downsides of a powerful, widely applicable but potentially fallible technique. Int. J. Epidemiol. 45, 1717–1726 (2016).
Leslie, R., O’Donnell, C. J. & Johnson, A. D. GRASP: Analysis of genotype-phenotype results from 1390 genome-wide association studies and corresponding open access database. Bioinformatics 30, i185–i194 (2014).
Burgess, S. et al. Guidelines for performing Mendelian randomization investigations. Wellcome Open Res. 4, 186 (2019).
Bowden, J., Davey Smith, G., Haycock, P. C. & Burgess, S. Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. Genet. Epidemiol. 40, 304–314 (2016).
Hartwig, F. P., Davey Smith, G. & Bowden, J. Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption. Int. J. Epidemiol. 46, 1985–1998 (2017).
Hemani, G., Bowden, J. & Davey Smith, G. Evaluating the potential role of pleiotropy in Mendelian randomization studies. Hum. Mol. Genet. 27, R195–R208 (2018).
Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with invalid instruments: Effect estimation and bias detection through Egger regression. Int. J. Epidemiol. 44, 512–525 (2015).
Verbanck, M., Chen, C. Y., Neale, B. & Do, R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat. Genet. 50, 693–698 (2018).
Kamat, M. A. et al. PhenoScanner V2: An expanded tool for searching human genotype-phenotype associations. Bioinformatics 35, 4851–4853 (2019).
Kousathanas, A. et al. Whole-genome sequencing reveals host factors underlying critical COVID-19. Nature 607, 97–103 (2022).
Skrivankova, V. W. et al. Strengthening the reporting of observational studies in epidemiology using mendelian randomisation (STROBE-MR): Explanation and elaboration. BMJ 375, n2233 (2021).
Burgess, S., Davies, N. M. & Thompson, S. G. Instrumental variable analysis with a nonlinear exposure-outcome relationship. Epidemiology 25, 877–885 (2014).
Benyamin, B. et al. Novel loci affecting iron homeostasis and their effects in individuals at risk for hemochromatosis. Nat. Commun. 5, 4926 (2014).
Gill, D. et al. Associations of genetically determined iron status across the phenome: A Mendelian randomization study. PLoS Med. 16, e1002833 (2019).
Alhazzani, W. et al. Surviving sepsis campaign guidelines on the management of adults with coronavirus disease 2019 (COVID-19) in the ICU: First update. Crit. Care Med. 49, e219–e234 (2021).
Sun, Y., Zhou, J. & Ye, K. Extensive Mendelian randomization study identifies potential causal risk factors for severe COVID-19. Commun. Med. 1, 59 (2021).
Bastin, A. et al. Iron chelator or iron supplement consumption in COVID-19? The role of iron with severity infection. Biol. Trace Elem. Res. https://doi.org/10.1007/s12011-021-03048-8 (2021).
doi: 10.1007/s12011-021-03048-8
Colafrancesco, S., Alessandri, C., Conti, F. & Priori, R. COVID-19 gone bad: A new character in the spectrum of the hyperferritinemic syndrome? Autoimmun. Rev. 19, 102573–102573 (2020).
Weiss, G., Ganz, T. & Goodnough, L. T. Anemia of inflammation. Blood 133, 40–50 (2019).
Sazawal, S. et al. Effects of routine prophylactic supplementation with iron and folic acid on admission to hospital and mortality in preschool children in a high malaria transmission setting: Community-based, randomised, placebo-controlled trial. Lancet 367, 133–143 (2006).
Habib, H. M., Ibrahim, S., Zaim, A. & Ibrahim, W. H. The role of iron in the pathogenesis of COVID-19 and possible treatment with lactoferrin and other iron chelators. Biomed. Pharmacother. 136, 111228 (2021).
Poonkuzhi Naseef, P. et al. Therapeutic potential of induced iron depletion using iron chelators in Covid-19. Saudi J. Biol. Sci. 29, 1947–1956 (2022).
Lehmann, C., Aali, M., Zhou, J. & Holbein, B. Comparison of treatment effects of different iron chelators in experimental models of sepsis. Life 11, 57 (2021).
Campione, E. et al. Lactoferrin as potential supplementary nutraceutical agent in COVID-19 patients: In vitro and in vivo preliminary evidences. BioRxiv 47, 4184 (2020).
Slob, E. A. W. & Burgess, S. A comparison of robust Mendelian randomization methods using summary data. Genet. Epidemiol. 44, 313–329 (2020).
Leligdowicz, A. & Matthay, M. A. Heterogeneity in sepsis: New biological evidence with clinical applications. Crit. care 23, 80–80 (2019).
Labrecque, J. A. & Swanson, S. A. Interpretation and potential biases of Mendelian randomization estimates with time-varying exposures. Am. J. Epidemiol. 188, 231–238 (2019).